Davita Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Direxion Daily TSLA Bull 2X Shares trades at $8.31. The key difference: Davita Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| DVA | TSLL | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $23.03 |
52-Week Low | $103.87 | $6.74 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.11, up 5.6% today. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages. The ETF, which aims to deliver twice Tesla's daily returns, lacks fundamental metrics as it is a leveraged product. Recent news highlights its volatility and investor focus on Tesla's performance.
The outlook for TSLL is tied to Tesla's stock volatility, offering amplified gains but significant risks. Key opportunities include potential upside from Tesla's growth, while risks involve high volatility and decay from daily rebalancing. Investors should be cautious due to the leveraged structure.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →